NHS to ensure people eligible for very high-risk breast screening are referred
Secondary breast cancer is an important risk factor after receiving radiotherapy for Hodgkin lymphoma
Read More
Tag: Hodgkin lymphoma
Final NICE nod for Takeda’s Adcetris in Hodgkin’s lymphoma
Certain patients with Hodgkin’s Lymphoma living in England and Wales can now expect routine access to Takeda’s Adcetris on the NHS after NICE deemed the drug a cost-effective use of resources in some scenarios.
Read More
MSD’s Keytruda wins EU green light in Hodgkin lymphoma
European regulators have expanded the reach of MSD’s Keytruda to include some patients with classical Hodgkin lymphoma (cHL), a type of lymphoma that develops in white blood cells of which there are around 66,000 new cases around the globe every year.
Read More
NICE u-turn recommends some access to Takeda’s Adcetris
It is now looking likely that some patients with relapsed/refractory (R/R) Hodgkin lymphoma will be able to get routine access to Takeda’s Adcetris on the NHS after a major u-turn by cost regulators.
Read More
US approves Merck’s Keytruda for Hodgkin lymphoma
Merck’s immunotherapy Keytruda has been approved by US regulators to treat both adult and paediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
